<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4074">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520620</url>
  </required_header>
  <id_info>
    <org_study_id>20CH089</org_study_id>
    <secondary_id>2020-001823-15</secondary_id>
    <nct_id>NCT04520620</nct_id>
  </id_info>
  <brief_title>Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention</brief_title>
  <acronym>COV-ENOX</acronym>
  <official_title>Evaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with COVID-19 have special demographic characteristics including thromboembolic risk&#xD;
      factors .&#xD;
&#xD;
      The pharmacokinetics of enoxaparin administered subcutaneously in the intensive care unit&#xD;
      patient are not described.&#xD;
&#xD;
      Finally, given the lack of knowledge on the pharmacokinetic/pharmacodynamic properties of&#xD;
      enoxaparin in intensive care unit patients infected with SARS-CoV-2, we propose to conduct a&#xD;
      prospective multicenter cohort study to collect the biological data necessary for its study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      D-dimers greater than 1 μg/mL are a prognostic factor for 28-day mortality (odds ratio=18,&#xD;
      2-128). The use of preventive doses of enoxaparin (4,000 to 6,000 anti-Xa per day) or&#xD;
      unfractionated heparin (10,000 to 15,000 IU per day) has been associated with a reduction in&#xD;
      mortality of approximately one-third in patients with D-dimer levels greater than 3 μg/mL or&#xD;
      those with sepsis-induced coagulopathy (SIC (sepsis-induced coagulopathy) score &gt; 4)&#xD;
&#xD;
      For the intensive care unit patient, the preventive enoxaparin dosages were increased to&#xD;
      4,000 anti-Xa IU twice daily and to 6,000 anti-Xa IU twice daily if the patient weighs more&#xD;
      than 120 kg. Curative treatment is even proposed in cases of marked inflammatory syndrome&#xD;
      and/or hypercoagulability (e.g. fibrinogen &gt; 8 g/L or D-Dimer &gt; 3 μg/mL or 3000 ng/mL) even&#xD;
      without symptomatic thrombosis.&#xD;
&#xD;
      Given the lack of data on the use of these high &quot;prophylactic&quot; doses of enoxaparin, it is&#xD;
      proposed that anti-Xa activity be monitored after the 3rd injection, and then regularly in&#xD;
      the event of renal failure (because LMWHs are renally eliminated), to look for overdosage&#xD;
      exposing a higher risk of bleeding. It is also proposed to regularly monitor (at least every&#xD;
      48 hours) the hemostasis of patients in search of multivisceral failure, or of coagulopathy&#xD;
      of consumption which will require a re-evaluation of the heparin therapy dosage, these events&#xD;
      being associated with an increased risk of haemorrhage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    End of the COVID 19 epidemic in the region and decision to participate in a national study on&#xD;
    the same subject (COVI-DOSE).&#xD;
  </why_stopped>
  <start_date type="Actual">May 2, 2020</start_date>
  <completion_date type="Actual">July 10, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of anti-Xa activity</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Measure of anti-Xa activity by chromogenic method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of hemorrhagic risk</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Hemorrhagic risk is composite of :&#xD;
Major haemorrhage as defined by the International Society on Thrombosis and Haemostasis (ISTH) definition&#xD;
clinically significant haemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolic events</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Venous thromboembolic events is composite of:&#xD;
symptomatic or symptomatic proximal deep vein thrombosis&#xD;
asymptomatic or symptomatic pulmonary embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis individual patient characteristics by the biomarker of Kidney function</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Rate of creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis individual patient characteristics by the biomarker of inflammation</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Biomarker of inflammation is composite of C-reactive protein (CRP) and inflammatory cytokines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis individual patient characteristics by the biomarker of coagulation</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Biomarker of coagulation is composite of fibrinogen and D-Dimers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographic characteristics</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Analysis of weight, age, sex, height, presence of a high thrombotic risk factor (history of venous thrombotics, active cancer, invasive mechanical ventilation).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>enoxaparin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients infected by SARS-CoV-2 in intensive care unit with enoxaparin treatment will be included.&#xD;
They will have enoxaparin pharmacokinetic and ultrasound of the lower limbs at 7, 14 and 21 days after inclusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovenox 40 MG in 0.4 mL Prefilled Syringe</intervention_name>
    <description>Patients with a high thrombotic risk:&#xD;
In patients with a BMI included between &lt; 30 kg/m² and &gt; 30 kg/m² without added thrombotic risk factor:&#xD;
Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization&#xD;
if weight &gt; 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization&#xD;
Patients with a very high thrombotic risk:&#xD;
In patients with a BMI &gt; 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen &gt; 8 g/L or D-Dimer &gt; 3 μg/ml or 3000 ng/ml)&#xD;
* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours</description>
    <arm_group_label>enoxaparin treatment</arm_group_label>
    <other_name>enoxaparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound of the lower limbs</intervention_name>
    <description>A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.</description>
    <arm_group_label>enoxaparin treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged &gt; 18 ans&#xD;
&#xD;
          -  SARS-CoV-2 infected intensive care unit patients&#xD;
&#xD;
          -  Diagnosis of SARS-CoV-2 respiratory infection was made with a nasopharyngeal swab or a&#xD;
             deep respiratory specimen.&#xD;
&#xD;
          -  Patient receiving enoxaparin treatment as part of care or as part of a clinical trial&#xD;
             for the prevention or treatment of thromboembolic venous disease.&#xD;
&#xD;
          -  Patient affiliated or entitled to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine clearance according to Cockcroft and Gault &lt;30ml/min.&#xD;
&#xD;
          -  Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low&#xD;
             molecular weight heparins (LMWHs)&#xD;
&#xD;
          -  History of immune-mediated heparin-induced thrombocytopenia (HIT) in the last 100 days&#xD;
             or in the presence of circulating antibodies&#xD;
&#xD;
          -  Active clinically significant bleeding or a condition associated with a high risk of&#xD;
             bleeding, such as a recent hemorrhagic stroke, gastrointestinal ulcer, the presence of&#xD;
             a malignant tumour at high risk of bleeding, recent brain, spinal or ophthalmologic&#xD;
             surgery, known or suspected esophageal varices, arteriovenous malformations, vascular&#xD;
             aneurysm or major intrarachidian or intracerebral vascular abnormalities.&#xD;
&#xD;
          -  Spinal, epidural or locoregional anaesthesia or anaesthesia when enoxaparin sodium is&#xD;
             used for curative treatment within the previous 24 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul ZUFFEREY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupement Hospitalier des portes de Province</name>
      <address>
        <city>Montélimar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Roanne</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>enoxaparin</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>SARS-Co-V-2</keyword>
  <keyword>Lovenox</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

